What Market Access Data Should a Biotech Gather Before Setting Its Launch Price

List price is only the opening figure in a longer negotiation. What you earn per patient depends on rebates, fees, coverage restrictions and patient cost-sharing, most of which you cannot control after launch. Market access data shows how much of the list price will survive that journey.

Concentration makes this more pressing. The FTC's 2024 interim report on pharmacy benefit managers found that the three largest PBMs processed nearly 80 percent of the roughly 6.6 billion prescriptions dispensed in the US in 2023. The top six handled more than 90 percent. A handful of buyers decide your access to the market. If you are still working out where access sits in your plan, our guide to market access in launch planning covers that. This piece assumes you are ready to gather the evidence.

Payer Coverage and Policy Data

Start with how payers manage your therapeutic area today. Pull the medical and pharmacy policies for your closest comparators. Note which ones require prior authorization, step therapy through cheaper agents, or dispensing through a specialty pharmacy. Record the share of covered lives under each rule, not just whether a rule exists. A drug that is "covered" but restricted for most lives behaves very differently from one with open access. Then add payer interviews. Ten to fifteen conversations with medical and pharmacy directors usually surface the evidence thresholds that desk research misses.

PBM and Channel Data

Map which PBMs control formulary decisions for your patient population, and what rebate expectations look like in your category. The same FTC report found that pharmacies affiliated with the three largest PBMs account for nearly 70 percent of specialty drug revenue. If your product is specialty, channel is not a detail. Gather typical rebate ranges, distribution fees, and whether competing brands trade discounts for formulary position. This tells you how much gross-to-net erosion to expect, and therefore how much list price headroom you need.

Government Program Data

Government programs set floors that your commercial deals cannot ignore.

Medicaid Rebates and Best Price

For innovator drugs, the Medicaid rebate is the greater of 23.1 percent of the average manufacturer price (AMP) or the gap between AMP and your best price, as described in CMS guidance and a Health Affairs explainer. So a deep discount to one commercial buyer can raise your rebate to every state program. An inflation-based penalty also applies if prices rise faster than inflation, which makes your launch price the baseline for all future increases. Model both before promising any payer an outsized discount.

Medicare Negotiation Timelines

Under the Inflation Reduction Act, Medicare can negotiate prices once a small molecule is seven years past approval, or a biologic eleven, according to KFF. Orphan-only drugs have an exclusion that a 2025 law broadened. Certain small biotech drugs are exempt for 2026 through 2028. Check which rules apply to you, because they decide how long your price stays unchallenged.

Patient and Treatment Pathway Data

Finally, collect epidemiology, diagnosis rates and the real treatment pathway, along with the expected split between commercial, Medicare and Medicaid patients. Payer mix moves net price per patient more than most teams expect. Add out-of-pocket exposure under Part D and commercial plans, since high cost-sharing drives abandonment at the pharmacy counter. Include comparator pricing and any published value benchmarks in your indication.

Data does not set a price; sequence does. First, build a net price waterfall from list price through expected rebates, fees and program discounts. Second, test it against payer feedback on value and evidence gaps. Third, stress-test the result against Medicaid best price and the negotiation timeline. What comes out is a corridor, with a floor your economics need and a ceiling payers will tolerate. The launch price sits inside it. If the corridor turns out to be empty, you want to learn that two years before launch, not two months.

Common Gaps in Early Biotech Pricing Work

Three gaps appear again and again. Teams lean on a single comparator and miss the wider treatment pathway. They interview payers after pivotal trial design is closed, when feedback can no longer change endpoints. And they treat government pricing as back-office compliance rather than a pricing input. Each is cheap to fix if caught early.

How Illumination Strategy Supports This Work

Illumination Strategy helps biotech founders and commercial leads build this evidence base before pricing decisions harden. We run payer research, build net price models and pressure-test assumptions against the rules above, so your launch price reflects how access actually works.

What is market access data in biotech?

Market access data is the evidence showing whether payers will cover your drug and at what net price. It includes coverage policies, rebate benchmarks, channel structure, government program rules, patient cost-sharing and payer research. Biotechs use it to forecast net revenue and to set a launch price that survives contracting.

When should a biotech start collecting market access data?

Ideally before pivotal trial design is finalised, usually two to three years before launch. Early payer feedback can still shape endpoints, comparators and patient-reported outcomes. Waiting until the filing stage leaves little room to act on what you learn, and pricing assumptions harden quickly once they appear in investor models.

How many payer interviews are enough?

Ten to fifteen well-chosen interviews usually reveal consistent themes within one therapeutic area. Include national and regional commercial plans, a Medicare Part D sponsor, a Medicaid representative and at least one PBM. Recruitment quality matters more than volume. Add more only if answers diverge sharply between segments.

What is the difference between list price and net price?

List price is the published price before any concessions. Net price is what the manufacturer keeps after rebates, fees, chargebacks and program discounts. The gap between them, often called gross-to-net, can be large in competitive classes. Launch decisions should rest on net price, because that figure drives revenue.

Why does Medicaid best price matter when setting a launch price?

Medicaid rebates for innovator drugs equal the greater of 23.1 percent of AMP or the difference between AMP and your best price. A deep discount offered to one commercial buyer can therefore reset your rebate to every state program. It limits how aggressively you can contract, so model it before negotiations begin.

Does the Inflation Reduction Act affect launch pricing for small biotechs?

Yes, mainly through timing. Small molecules become negotiation-eligible seven years after approval and biologics after eleven. Orphan-only products have an exclusion, and certain small biotech drugs are exempt from 2026 to 2028. These rules affect how long a price holds, so check eligibility when building long-range revenue models.

Can a biotech use market access data from a different therapeutic area?

Only as a rough guide. Payer behaviour varies widely by disease, patient population and treatment setting. Oncology drugs sit under different rules than chronic primary care products, and rare disease payers weigh evidence differently again. Use adjacent-category data to frame questions, then validate with research in your own indication.

Is it better to do market access research in-house or hire a consultant?

Small teams often lack payer contacts and time, so an outside partner can speed things up and bring benchmark data. In-house work suits companies with an experienced access lead. Many biotechs combine both: internal ownership of strategy, external support for interviews and modelling. Document assumptions either way so findings carry into pricing.